CLDX - thanks Exwannabe, I was just trying to relay what Dr. Vahdat appeared to say at the Analyst Day. I do not know what they need to go further, but I believe she said "same and they are still in the ballgame". Obviously the better the results the better the chances going forward. If I remember correctly she said the data and the FDA will tell them which way to go into P3. They may proceed on some promising sub-group data. Few treatment choices with any positive effect on triple negative, so the hurdle is low.
With respect to EGFRvIII positive or negative having a worse OS prognosis, any thoughts for the Rindo P3?, that journal article threw me for a loop.
News 
Market Data 
Discover 
